ValuEngine lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a strong sell rating in a research report released on Sunday.

A number of other research firms have also commented on ZIOP. HC Wainwright reissued a buy rating and issued a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Zacks Investment Research raised ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 target price for the company in a report on Friday, November 10th. Finally, Raymond James Financial reissued a hold rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $12.75.

ZIOPHARM Oncology (NASDAQ ZIOP) traded up $0.17 during mid-day trading on Friday, reaching $4.61. The company had a trading volume of 1,445,100 shares, compared to its average volume of 1,906,150. ZIOPHARM Oncology has a one year low of $3.90 and a one year high of $7.88. The company has a market cap of $623.57, a price-to-earnings ratio of -8.87 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the business earned ($0.11) EPS. research analysts predict that ZIOPHARM Oncology will post -0.54 EPS for the current year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of ZIOPHARM Oncology stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after buying an additional 553,933 shares during the last quarter. State Street Corp boosted its stake in shares of ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after buying an additional 517,057 shares during the last quarter. Northern Trust Corp boosted its stake in shares of ZIOPHARM Oncology by 10.1% in the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after buying an additional 149,067 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of ZIOPHARM Oncology by 6.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock worth $3,799,000 after buying an additional 38,440 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of ZIOPHARM Oncology by 2.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,533 shares of the biotechnology company’s stock worth $3,804,000 after buying an additional 13,127 shares during the last quarter. Hedge funds and other institutional investors own 40.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/ziopharm-oncology-ziop-cut-to-strong-sell-at-valuengine/1794472.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with Analyst Ratings Network's FREE daily email newsletter.